Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
From gut to tumour: leveraging microbiome-derived innate immune ligands to enhance anti-tumourigenic immune responses
EF 2024-25
Résumé
Development and progression of colorectal cancer (CRC) has been shown to be influenced by the gut microbiome. For this reason, we intend to investigate the effects microbial products that may effect tumour growth and how the immune system responds to the tumour. A bacterial product of interest are the stimulator of interferon gene (STING) ligands, specifically cyclic dinucleotides (CDNs). CDNs are produced by bacteria in response to cytosolic DNA, which can be released by apoptotic tumour cells. When CDNs stimulate the STING pathway, type 1 interferons are produced which are crucial for the tumour immune response. It is currently unclear if microbiome derived CDNs have an effect on the tumour immune response. We hypothesize that introducing CDN-producing bacteria species to the gut microbiome will promote a pro-inflammatory immune response suppressing tumour growth, which could work in synergy with current immune checkpoint inhibitor therapies. To achieve this, we will use two different tumour mouse models and modulate the gut microbiome using either wildtype B. subtilisorB. subtilis engineered to produce CDNs. We will measure tumour volume and weight, and profile the immune cells that inflitrate the tumours. We will also treat both groups of mice with the immune checkpoint inhibitor anti-PD1 and investigate synergistic effects of that with bacterial-derived CDNs on tumour infiltrating T cells. This study will provide insight into how microbial products can impact the tumour immune response, and highlight possibilities for microbiome-targeted therapies such as probiotics or fecal microbiota transplants, which can be given alongside immune checkpoint blockade therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529765
Name
Denney Madison
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
From gut to tumour: leveraging microbiome-derived innate immune ligands to enhance anti-tumourigenic immune responses
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacterial Products; Cancer Immunotherapy; Colorectal Cancer; Cyclic Dinucleotides; Gut Bacteria; Gut Microbiome; Immune Checkpoint Inhibition; Lymphocytes; Sting; Tumour Immunity
Abstract
Development and progression of colorectal cancer (CRC) has been shown to be influenced by the gut microbiome. For this reason, we intend to investigate the effects microbial products that may effect tumour growth and how the immune system responds to the tumour. A bacterial product of interest are the stimulator of interferon gene (STING) ligands, specifically cyclic dinucleotides (CDNs). CDNs are produced by bacteria in response to cytosolic DNA, which can be released by apoptotic tumour cells. When CDNs stimulate the STING pathway, type 1 interferons are produced which are crucial for the tumour immune response. It is currently unclear if microbiome derived CDNs have an effect on the tumour immune response. We hypothesize that introducing CDN-producing bacteria species to the gut microbiome will promote a pro-inflammatory immune response suppressing tumour growth, which could work in synergy with current immune checkpoint inhibitor therapies. To achieve this, we will use two different tumour mouse models and modulate the gut microbiome using either wildtype B. subtilisorB. subtilis engineered to produce CDNs. We will measure tumour volume and weight, and profile the immune cells that inflitrate the tumours. We will also treat both groups of mice with the immune checkpoint inhibitor anti-PD1 and investigate synergistic effects of that with bacterial-derived CDNs on tumour infiltrating T cells. This study will provide insight into how microbial products can impact the tumour immune response, and highlight possibilities for microbiome-targeted therapies such as probiotics or fecal microbiota transplants, which can be given alongside immune checkpoint blockade therapy.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Denney, Madison
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~